Prefusion PIV F immunogens and their use

Patent metadata

Field	Value
Publication number	US-11078239-B2
Application number	US-201716344772-A
Country	US
Kind code	B2
Filing date	Oct 25, 2017
Priority date	Oct 25, 2016
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

First claim

It is claimed:

1. An immunogen, comprising:
a recombinant human parainfluenza virus hPIV3 F ectodomain trimer comprising protomers comprising one or more amino acid substitutions that stabilize the hPIV3 ectodomain trimer in a prefusion conformation, wherein the one or more amino acid substitutions comprise
463V and/or 474Y cavity filling substitutions; and/or
one or more of the following sets of substitutions to form a disulfide bond to stabilize the hPIV3 ectodomain trimer in a prefusion conformation:
162C and 168C;
213C and 230C;
170C and 242C;
216C and 221C;
85C and 222C; and
172C and 238C; and
wherein amino acid substitution numbering is according to a reference hPIV3 F sequence set forth as SEQ ID NO: 9.

2. The immunogen of claim 1 , wherein the one or more amino acid substitutions comprise:
the 463V and/or 474Y cavity filling substitutions; and
the one or more of the following sets of substitutions to form a disulfide bond to stabilize the hPIV3 ectodomain trimer in a prefusion conformation:
162C and 168C;
170C and 242C;
213C and 230C;
216C and 221C;
85C and 222C; and
172C and 238C.

3. The immunogen of claim 1 , wherein the one or more amino acid substitutions comprise:
162C and 168C substitutions to form a disulfide bond, 213C and 230C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions;
162C and 168C substitutions to form a disulfide bond, 216C and 221C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions;
162C and 168C substitutions to form a disulfide bond, 85C and 222C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions;
213C and 230C substitutions to form a disulfide bond, 170C and 242C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions;
213C and 230C substitutions to form a disulfide bond, 216C and 221C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions;
213C and 230C substitutions to form a disulfide bond, 85C and 222C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions; or
172C and 238C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions.

4. The immunogen of claim 1 , wherein the 162C, 170C, 168C, 213C, 230C, 216C, 221C, 85C, 222C, 216C, 221C, 242C, 172C, 238C, 463V, and 474Y substitutions are Q162C, V170C, L168C, I213C, G230C, D216C, L221C, G85C, Q222C, D216C, L221C, I242C, I172C, N238C, A463V, and I474Y substitutions, respectively.

5. The immunogen of claim 1 , wherein the protomers further comprise a mutation to inhibit cleavage of a F 2 /F 1 protease cleavage site.

6. The immunogen of claim 5 , wherein the mutation to inhibit cleavage of a F 2 /F 1 protease cleavage site comprises a K108E substitution.

7. The immunogen of claim 1 , wherein an N-terminal residue of the protomers is one of hPIV3 residues 15-25 and a C-terminal residue of the protomers is one of hPIV3 F residues 475-493, wherein the residue numbering is according to the reference hPIV3 F sequence set forth as SEQ ID NO: 9.

8. The immunogen of claim 1 , wherein the protomers comprise or consist essentially of hPIV3 residues 19-484 and comprise the one or more amino acid substitutions to stabilize the trimer in the prefusion conformation and the mutation to inhibit cleavage of the F 2 /F 1 protease cleavage site, wherein the residue numbering is according to the reference hPIV3 F sequence set forth as SEQ ID NO: 9.

9. The immunogen of claim 1 , wherein the protomers comprise or consist essentially of the amino acid sequence set forth as residues 1-463 of any one of SEQ ID NOs: 10-26 or 39-50, or an amino acid sequence at least 90% identical thereto.

10. The immunogen of claim 1 , wherein a C-terminal residue of the protomers in the ectodomain is linked to a trimerization domain by a peptide linker, or is directly linked to the trimerization domain.

11. The immunogen of claim 10 , wherein the trimerization domain is a GCN4 trimerization domain.

12. The immunogen of claim 11 , wherein the protomers comprise or consist essentially of the amino acid sequence set forth as any one of SEQ ID NOS: 10-26 or 39-50, or an amino acid sequence at least 90% identical thereto.

13. The immunogen of claim 1 , wherein the protomers further comprise one or more additional amino acid substitutions.

14. The immunogen of claim 1 , wherein the recombinant hPIV3 F ectodomain trimer specifically binds to a hPIV3 F prefusion specific antibody.

15. The immunogen of claim 1 , wherein the recombinant hPIV3 F ectodomain trimer is soluble.

16. The immunogen of claim 1 , wherein the C-terminal residue of the protomers in the F ectodomain is linked to a transmembrane domain by a peptide linker, or is directly linked to the transmembrane domain.

17. The immunogen of claim 16 , wherein the protomers comprise the amino acid sequence set forth as any one of SEQ ID NOs: 51-65 or 75-80, or an amino acid sequence at least 90% identical thereto.

18. The immunogen of claim 1 , wherein the C-terminal residue of the protomers in the F ectodomain is linked to a protein nanoparticle subunit by a peptide linker, or is directly linked to the protein nanoparticle subunit.

19. A protein nanoparticle, comprising the immunogen of claim 18 .

20. A virus-like particle comprising the immunogen of claim 1 .

21. An immunogenic composition comprising the immunogen of claim 1 .

22. A method of inducing an immune response to hPIV3 F protein in a subject, comprising administering to the subject an effective amount of the immunogen of claim 1 to generate the immune response.

23. The method of claim 22 , wherein the immune response inhibits an hPIV3 infection.

24. The immunogen of claim 1 , wherein:
the one or more amino acid substitutions comprise 162C and 168C substitutions to form a disulfide bond, 213C and 230C substitutions to form a disulfide bond, and 463V and 474Y cavity filling substitutions; and
a C-terminal residue of protomers in the ectodomain is linked to a GCN4 trimerization domain by a peptide linker, or is directly linked to the trimerization domain.

Assignees

• Us Health
• Inst Res Biomedicine

Inventors

• Zhang Baoshan
• Stewart-Jones Guillaume
• Zhou Tongqing
• Mascola John
• Xu Kai
• Yang Yongping
• Thomas Paul
• Chuang Gwo-Yu
• Ou Li
• Kwong Peter
• Tsybovsky Yaroslav
• Kong Wing-Pui
• Druz Aliaksandr
• Corti Davide
• Lanzavecchia Antonio

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C12N2760/00034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18634

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K2319/50

  containing protease site · CPC title

• A61P31/14

  for RNA viruses · CPC title